中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
CHINESE JOURNAL OF MATERNAL AND CHILD HEALTH RESEARCH
2015年
2期
246-247,257
,共3页
宫颈癌%SiHa细胞%苦参碱%顺铂%肺癌肿瘤抑制因子1
宮頸癌%SiHa細胞%苦參堿%順鉑%肺癌腫瘤抑製因子1
궁경암%SiHa세포%고삼감%순박%폐암종류억제인자1
cervical cancer%SiHa cells%cisplatin%matrine%tumor suppressor in lung cancer-1(TSLC1)
目的：探讨苦参碱联合顺铂抑制人宫颈癌SiHa细胞及对肺癌肿瘤抑制因子1（TSLC1）基因表达的效果。方法取对数生长期的SiHa分为对照组、苦参组、顺铂组和联合组，采用四甲基偶氮唑蓝比色法（ MTT）测定4组联合干预SiHa细胞2d后的抑制率；采用实时荧光定量（ RT－PCR）技术检测各组处理后TSLC1基因mRNA表达水平的变化。结果对照组、顺铂组、苦参碱组和联合组的SiHa细胞抑制率分别为0、61．24％、70．31％和74．20％，药物干预组均高于对照组（ t 值分别为14．21、17．44、11．20，均P＜0．05），同时联合组高于苦参碱和顺铂单独干预（t值分别为4．47、3．21，均P＜0．05），而顺铂和苦参碱组间差异无统计学意义（t＝0．71，P＞0．05）。对照组、苦参碱组、顺铂组和联合组干预SiHa细胞后TSLC1mRNA表达量分别为1．00±0．00μg／mL，23．53±0．01μg／mL，84．33±0．03μg／mL和90．23±0．01μg／mL，苦参碱组、顺铂组和联合组干预组明显高于对照组（ z值分别为9．41、10．72、13．23，均P＜0．05），其中苦参碱组和联合组TSLC1mRNA表达量组间比较差异无统计学意义（z＝1．24，P＞0．05），但均高于顺铂组（z值分别为6．04、5．47，均P＜0．05）；析因设计方差分析结果表明顺铂和苦参碱均为SiHa细胞抑制率和TSLC1基因表达的影响因素，而且两者存在交互作用，联合应用使效果增加。结论苦参碱联合顺铂能抑制人宫颈癌SiHa细胞增殖，提高TSLC1mRNA表达量。
目的：探討苦參堿聯閤順鉑抑製人宮頸癌SiHa細胞及對肺癌腫瘤抑製因子1（TSLC1）基因錶達的效果。方法取對數生長期的SiHa分為對照組、苦參組、順鉑組和聯閤組，採用四甲基偶氮唑藍比色法（ MTT）測定4組聯閤榦預SiHa細胞2d後的抑製率；採用實時熒光定量（ RT－PCR）技術檢測各組處理後TSLC1基因mRNA錶達水平的變化。結果對照組、順鉑組、苦參堿組和聯閤組的SiHa細胞抑製率分彆為0、61．24％、70．31％和74．20％，藥物榦預組均高于對照組（ t 值分彆為14．21、17．44、11．20，均P＜0．05），同時聯閤組高于苦參堿和順鉑單獨榦預（t值分彆為4．47、3．21，均P＜0．05），而順鉑和苦參堿組間差異無統計學意義（t＝0．71，P＞0．05）。對照組、苦參堿組、順鉑組和聯閤組榦預SiHa細胞後TSLC1mRNA錶達量分彆為1．00±0．00μg／mL，23．53±0．01μg／mL，84．33±0．03μg／mL和90．23±0．01μg／mL，苦參堿組、順鉑組和聯閤組榦預組明顯高于對照組（ z值分彆為9．41、10．72、13．23，均P＜0．05），其中苦參堿組和聯閤組TSLC1mRNA錶達量組間比較差異無統計學意義（z＝1．24，P＞0．05），但均高于順鉑組（z值分彆為6．04、5．47，均P＜0．05）；析因設計方差分析結果錶明順鉑和苦參堿均為SiHa細胞抑製率和TSLC1基因錶達的影響因素，而且兩者存在交互作用，聯閤應用使效果增加。結論苦參堿聯閤順鉑能抑製人宮頸癌SiHa細胞增殖，提高TSLC1mRNA錶達量。
목적：탐토고삼감연합순박억제인궁경암SiHa세포급대폐암종류억제인자1（TSLC1）기인표체적효과。방법취대수생장기적SiHa분위대조조、고삼조、순박조화연합조，채용사갑기우담서람비색법（ MTT）측정4조연합간예SiHa세포2d후적억제솔；채용실시형광정량（ RT－PCR）기술검측각조처리후TSLC1기인mRNA표체수평적변화。결과대조조、순박조、고삼감조화연합조적SiHa세포억제솔분별위0、61．24％、70．31％화74．20％，약물간예조균고우대조조（ t 치분별위14．21、17．44、11．20，균P＜0．05），동시연합조고우고삼감화순박단독간예（t치분별위4．47、3．21，균P＜0．05），이순박화고삼감조간차이무통계학의의（t＝0．71，P＞0．05）。대조조、고삼감조、순박조화연합조간예SiHa세포후TSLC1mRNA표체량분별위1．00±0．00μg／mL，23．53±0．01μg／mL，84．33±0．03μg／mL화90．23±0．01μg／mL，고삼감조、순박조화연합조간예조명현고우대조조（ z치분별위9．41、10．72、13．23，균P＜0．05），기중고삼감조화연합조TSLC1mRNA표체량조간비교차이무통계학의의（z＝1．24，P＞0．05），단균고우순박조（z치분별위6．04、5．47，균P＜0．05）；석인설계방차분석결과표명순박화고삼감균위SiHa세포억제솔화TSLC1기인표체적영향인소，이차량자존재교호작용，연합응용사효과증가。결론고삼감연합순박능억제인궁경암SiHa세포증식，제고TSLC1mRNA표체량。
Objective To investigate the effect of matrine combined with cisplatin on inhibiting human cervical cancer SiHa cells and on tumor suppressor in lung cancer 1 (TSLC1) gene expression.Methods Logarithmic growth phase of SiHa cells were divided into control group, matrine group, cisplatin group and combination group.Inhibition rate was measured with MTT method.The change of TSLC1 gene mRNA expression was detected by RT-PCR process in each group.Results Inhibition rates of SiHa cells in the control group, matrine group, cisplatin group and the combination group were 0, 61.24%, 70.31%and 74.20%, respectively.The inhibition rates of medicine intervention groups were higher than the control group (t value was 14.21, 17.44 and 11.20, respectively, all P<0.05), and the combination group was higher than cisplatin and matrine group (t value was 4.47 and 3.21, respectively, both P<0.05).There was no significant difference between cisplatin group and matrine group (t=0.71, P>0.05).The levels of TSLC1 mRNA expression after the intervention on SiHa cells in the control group, matrine group, cisplatin group and the combination group were 1.00 ±0.00μg/mL, 23.53 ±0.01μg/mL, 84.33 ±0.03μg/mL and 90.23 ±0.01μg/mL, respectively.Those of the medicine intervention groups were significantly higher than the control group (z was 9.41, 10.72 and 13.23, respectively, all P<0.05).There was no significant difference between matrine group and the combination group in TSLC1 mRNA expression level (z=1.24,P>0.05), but both of them were higher than cisplatin group (z value was 6.04 and 5.47, respectively, both P<0.05).Factorial design analysis of variance showed that cisplatin and matrine were influencing factors of inhibiting SiHa cells and TSLC1 gene expression.There was an interaction effect between them so that it generated increasing effect by combination.Conclusion Matrine combined with cisplatin can inhibit the proliferation of human cervical cancer SiHa cells and improve TSLC1 mRNA expression level.
